Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

PeptiDream Inc

Company price
6.695 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
100
Market Cap
899.97M

Momentum Score

…

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.70
Low
6.85
High
52 Week Price Range
5.88
Low
12.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

PeptiDream Inc is a Japan-based biotechnology company that leverages a proprietary peptide discovery platform to generate peptide drug candidates and to support partnered programs with pharmaceutical companies. Long-term growth may be driven by licensing and milestone revenues from collaborations, progression of its internal pipeline, and wider adoption of its discovery platform, which could support recurring partnership income.

Material risks include clinical and regulatory failure of its drug candidates, dependence on milestone and licensing payments with partner concentration, and limited liquidity and disclosure associated with its OTC Pink listing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.70
Dividend Yield
-
Revenue TTM
19204.00M
Revenue Per Share
148.82
Gross Profit TTM
8324.00M
Debt / Equity
0.33
ROE
-7.09%
Net Debt
-11651.58M
ROCE
-9.28%
Diluted EPS TTM
-0.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -5316.76M 20888.81M 4353.47M 6653.32M 4823.65M
Net income -3752.48M 15014.92M 3035.83M 7554.36M 3606.41M
Selling general administrative 7473.92M 6845.00M 7256.19M 6220.62M -
Selling and marketing expenses - 1743.00M - - -
Gross profit 7528.91M 34503.82M 17218.72M 18113.49M 7007.95M
Reconciled depreciation 2126.51M 2248.47M 2433.18M 1973.38M 633.01M
Ebit -4978.82M 21547.70M - 8965.97M 4368.97M
Ebitda -2850.46M 23796.17M - 10939.35M 5001.97M
Depreciation and amortization 2128.37M 2248.47M - 1973.38M 633.01M
Operating income -4978.82M 21113.84M 6773.05M 8980.20M 4418.14M
Other operating expenses 23516.22M 25562.68M - 17872.23M 4947.82M
Interest expense 500.75M 658.89M 2253.01M 2312.64M 0.00M
Tax provision -1562.92M 5873.88M 1317.64M -901.03M 1217.24M
Interest income 242.61M 411.24M 190.98M 189.05M 0.28M
Net interest income -257.70M -247.65M -2062.03M -2123.60M 0.12M
Income tax expense -1564.29M 5873.88M - -901.03M 1217.24M
Total revenue 18537.40M 46676.52M 28712.19M 26852.43M 9365.96M
Total operating expenses 12507.73M 13389.98M 21939.15M 9133.29M 2589.81M
Cost of revenue 11008.48M 12172.70M 11493.48M 8738.94M 2358.01M
Total other income expense net -337.94M -225.04M - -2326.87M 405.51M
Net income from continuing ops -3749.20M 15014.92M 3035.83M 7554.36M 3606.41M
Net income applicable to common shares - - - 7554.36M 3606.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 77100.41M 92769.83M 69464.01M 63865.20M 26619.17M
Intangible assets 2018.51M 2142.97M 2211.45M 2232.55M 75.50M
Other current assets 1157.11M 1130.91M 335.96M 550.96M 255.12M
Total liab 25527.18M 36007.53M 29114.30M 31823.74M 1620.57M
Total stockholder equity 51573.23M 56762.30M 40349.71M 32041.47M 24998.60M
Other current liab 1129.65M 2442.46M 712.84M 4259.65M 1170.81M
Common stock 3960.19M 3956.74M - 3956.74M 3956.74M
Capital stock 3956.74M 3956.74M 3956.74M 3956.74M 3956.74M
Retained earnings 45626.58M 49393.47M 27804.69M 23848.34M 17543.27M
Other liab - - - 2435.53M 348.89M
Good will 8377.98M 8370.68M 8370.68M 8370.68M -
Other assets - 0.00M - 0.00M 0.00M
Cash 28707.96M 48117.93M 19507.86M 5247.66M 11746.53M
Total current liabilities 23438.98M 18406.77M 8617.09M 11030.40M 1271.68M
Current deferred revenue 995.84M - - 3367.32M -
Net debt -11651.58M -28483.49M 2712.84M 15800.78M -11746.53M
Short term debt 17056.38M 2592.93M - 2690.65M -
Short long term debt 17041.51M 2592.93M 2586.26M 2690.65M -
Short long term debt total 17056.38M 19634.45M - 21048.45M -
Other stockholder equity 1987.13M 3412.09M - 4236.39M 3498.59M
Property plant equipment - - - 18125.42M 6437.15M
Total current assets 38953.79M 57209.63M 27225.08M 25072.71M 13863.30M
Net tangible assets - - - 21438.23M 24923.09M
Short term investments 6.25M 6.25M 6.25M 6.24M -
Net receivables 5895.36M 5282.89M 4970.86M 16589.15M 936.51M
Long term debt 0.00M 17041.51M 19634.45M 18357.80M -
Inventory 3193.35M 2671.66M 2404.16M 2678.70M 925.14M
Accounts payable 4257.10M 5332.04M 3203.56M 4080.10M 100.87M
Accumulated other comprehensive income -771.93M - - - -
Non currrent assets other 93.16M 2771.21M 46.85M 112.91M 6149.25M
Non current assets total 38146.62M 35560.19M 42238.93M 38792.49M 12755.86M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -300.00M 10558.46M 1302.54M -27377.22M -798.04M
Change to liabilities - - - 1453.71M 45.59M
Total cashflows from investing activities -2055.79M 8370.79M - -27377.22M -2283.45M
Net borrowings -2640.00M -2640.00M 1160.00M 21002.42M 21002.42M
Total cash from financing activities -4061.25M -2994.63M - 20789.45M 66.07M
Change to operating activities - - - 2096.30M -751.93M
Net income -3752.48M 20888.81M 3035.83M 6653.32M 4823.65M
Change in cash -19293.46M 28610.07M 14260.20M -6498.86M 4597.17M
Begin period cash flow 48001.43M 138.25M 5247.66M 11746.53M 7149.36M
End period cash flow 28707.96M 306.03M 19507.86M 5247.66M 11746.53M
Total cash from operating activities -13288.46M 23844.99M 12420.97M -82.93M 6654.71M
Issuance of capital stock 0.00M 18.75M - 0.00M 44.94M
Depreciation 2128.37M 2248.47M 2433.18M 1973.38M 633.01M
Other cashflows from investing activities 0.80M -111.17M - -10.51M -276.97M
Change to inventory -519.36M -267.50M 274.54M -656.49M -339.16M
Change to account receivables -584.94M -312.03M - -11286.61M 4844.64M
Sale purchase of stock -961.75M -0.16M -514.55M -0.17M -0.36M
Other cashflows from financing activities -389.82M -354.75M - 22469.62M 21.49M
Change to netincome - - - -1217.58M -1384.01M
Capital expenditures 1644.37M 2218.27M 1368.96M 3975.42M 1214.68M
Change in working capital -2153.60M 1107.37M 10813.44M -10385.53M 4616.29M
Other non cash items -9510.75M -399.66M -1421.73M 1675.90M -3418.24M
Free cash flow -14932.83M 21626.72M 11052.01M -4058.34M 5440.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PPTDF
PeptiDream Inc
-
-%
6.70 - 41.32 0.05 2.84 6.69 8.88
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

PeptiDream Inc

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.

3-25-23 Tonomachi, Kawasaki, Japan, 210-0821

81 4 4270 1300

763

Name Title Year Born
Dr. Patrick Crawford Reid Ph.D. Pres, CEO & Representative Director 1975
Dr. Kiyofumi Kaneshiro Ph.D. CFO, Exec. VP & Director NA
Dr. Keiichi Masuya Ph.D. COO, Exec. VP & Director 1969
Toshiyuki Iwata Head of Investor Relations NA
Yuko Okimoto Exec. Officer of IR PR Department NA
Dr. Patrick Crawford Reid Ph.D. President, CEO & Representative Director 1975
Ms. Kaseri Oura M.S., P.M.P. Executive Vice President of Operations 1975
Mr. Christian Cunningham Ph.D. Chief Scientific Officer NA
Ms. Yuko Okimoto IR & Public Relations Director NA
Mr. Kodo Shikata Ph.D. Executive Vice President of People & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…